Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Advancing a Novel Target Against Gastrointestinal Cancer to Undergo ADC Development in a Currently Underserved Indication

Advancing a Novel Target Against Gastrointestinal Cancer to Undergo ADC Development in a Currently Underserved Indication

2:30 pm - Wednesday 14th October 2026

Delving into novel ADC target FGFR2b, MUC17 and CDH17 to treat gastrointestinal cancer, an indication currently underserved by ADC therapies
Exploring preclinical and clinical development of CDH17 ADC in colorectal cancer
Complementing bispecific design and linker-payload DAR optimization for next generation bispecific ADCs

Speakers:

Yan Xia

Yan Xia

Director, ADC Research

Huadong Medicine Co.,Ltd